The agenda for the Transparency Council, which will meet on January 31st, is: Preparation of positions on drug evaluation: Venclyxto (venetoclaxum) as part of the drug program: "Treatment of patients with acute myeloid leukemia with venetoclax in combination with azacitidine (ICD-10 C92.0)",...
The US Food and Drug Administration has approved the use of the biological medicine frunevetmab to treat pain in cats suffering from osteoarthritis. It is the first of its kind to be approved by the FDA for use in an animal species.
The agenda includes: Preparation of positions on the evaluation of the drug Emgality (galcanezumabum) under the drug program: "Prophylactic treatment of patients with chronic migraine (ICD-10: G43)". Preparation of an opinion on the reimbursement of drugs containing the active substance...
The Presidium of the Supreme Medical Council, after reviewing the draft ordinance of the President of the National Health Fund on the terms of concluding and implementing contracts such as hospital treatment in the field of drug programs, submits the following comments to the draft ordinance. The...
The agenda is: Preparation of positions on drug evaluation: Inrebic (fedratinibum) under the drug program: "Treatment of primary myelofibrosis and secondary myelofibrosis in the course of polycythemia vera and essential thrombocythemia (ICD-10 D47.1)", Kesimpta (ofatumumabum) under the drug...
The European Commission (EC) has granted conditional marketing authorisation for sotorasib, a first-in-class KRASG12C inhibitor, for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic...
The draft ordinance of the Minister of Health amending the ordinance on enriching substances added to food was submitted for consultation.
The Council will meet on January 10 (Monday). The agenda is: Preparation of a position on the evaluation of the drug Jardiance (empagliflozinum) in the indication: chronic heart failure in adult patients with reduced left ventricular ejection fraction (LVEF ≤ 40%) and persistent disease symptoms...
The decision is related to the finding of a quality defect.
© 2023 Medexpress. All Rights Reserved
